Johnson & Johnson 14Fr Low Profile Introducer Kit Injury Lawsuit Lawyers

Johnson & Johnson MedTech Recall Raises Concerns About Blood Clot Formation, Vascular Complications, and Patient Safety During Critical Heart Procedures

What Parker Waichman LLP Found

• The FDA issued a safety alert involving certain Impella 14Fr Low Profile Introducer Kits.
• Three serious injuries have been linked to reported blood clot formation risks.
• The recall focuses on introducer kits used with the Impella CP with SmartAssist system.
• Blood clot complications may lead to vascular obstruction, ischemia, and permanent impairment.
• Multiple recalls and safety alerts have affected various Impella-related products in recent years.

FDA Highlights Recall Involving Certain Impella Introducer Kits

Patients undergoing high-risk cardiac procedures often depend on sophisticated medical devices designed to provide life-sustaining support during some of the most medically fragile moments of their lives. When concerns emerge regarding the safety of those devices, healthcare providers, patients, and families deserve clear information about the risks involved.

The U.S. Food and Drug Administration recently issued a safety alert concerning certain 14Fr Low Profile Introducer Kits used with Johnson & Johnson MedTech’s Impella CP with SmartAssist system. The warning followed reports that these introducer kits may increase the risk of thrombus formation, commonly known as blood clot development, within the device system. According to publicly available information, three serious injuries have already been associated with the issue.

The FDA emphasized that the concern is not related to the actual Impella heart pump itself. Instead, the issue involves specific introducer kits used to facilitate access to a patient’s vascular system during placement and removal of the device. Despite that distinction, certain Impella CP with SmartAssist systems are included in the recall because the affected introducer kits are necessary components for use with those devices.

This development is particularly significant because the Impella platform is often used in critically ill patients who are already facing severe cardiovascular conditions. Any complication that interferes with blood flow can have immediate and potentially devastating consequences.

As healthcare facilities evaluate their inventories and respond to the FDA’s warning, patients and families may be left with important questions regarding potential complications, long-term health effects, and legal rights when medical device failures allegedly contribute to injury.

Understanding the Role of the Impella CP with SmartAssist System

The Impella CP with SmartAssist is a temporary mechanical circulatory support device commonly referred to as a heart pump. It is designed to assist the heart in pumping blood when a patient’s cardiovascular system is unable to provide adequate circulation on its own.

Physicians may use the device during high-risk percutaneous coronary intervention procedures, often called PCI procedures, when treating severe coronary artery disease. The system is also used in patients suffering from cardiogenic shock, a life-threatening condition in which the heart suddenly cannot pump enough blood to meet the body’s needs.

The Impella device is inserted through a large blood vessel and positioned within the heart to help maintain circulation while physicians address underlying cardiac problems. Because of the complexity of these procedures, specialized introducer kits are used to safely access the vascular system and facilitate placement of the device.

Patients requiring Impella support are frequently among the sickest individuals in a hospital. Many already face significant cardiovascular instability, reduced blood flow to vital organs, and elevated risks of serious complications. Any device-related issue that further compromises circulation can create additional medical emergencies.

The FDA warning focuses on the introducer kits used during these procedures rather than the heart pump mechanism itself. Nevertheless, because the introducer kits play a critical role in the device’s operation, concerns regarding their safety remain extremely important.

The Blood Clot Risk Identified by the FDA

According to the FDA’s safety communication, Johnson & Johnson MedTech identified an increased risk of thrombus formation associated with certain recalled introducer kits.

A thrombus is a blood clot that forms within a blood vessel or medical device. While blood clot formation can occur in many clinical situations, device-related clots present unique dangers because they may obstruct circulation or break loose and travel elsewhere in the body.

The FDA explained that thrombus formation may develop within the sheath lumen or within the space between the catheter and the introducer sheath during prolonged support.

When blood flow becomes disrupted in these areas, clot formation may occur. If a clot remains in place, it can interfere with circulation near the vascular access site. If the clot becomes dislodged, however, the consequences may become significantly more severe.

A dislodged clot can travel through the bloodstream and obstruct smaller blood vessels downstream. This may result in ischemia, a condition in which tissues are deprived of oxygen-rich blood.

Without prompt intervention, ischemia can lead to tissue damage, organ injury, permanent disability, or limb-threatening complications.

The FDA further noted that, in less common circumstances, vascular occlusion could become irreversible if not corrected quickly. Permanent vascular damage may lead to long-term impairment and ongoing medical complications.

For patients already experiencing severe cardiac conditions, these additional risks can significantly complicate treatment and recovery.

Serious Injuries Have Already Been Reported

According to information released by the FDA, three serious injuries have been linked to the recalled introducer kits.

While public reports have not disclosed detailed patient information, the existence of reported injuries demonstrates that the safety concern is more than a theoretical risk.

Medical device recalls frequently begin after adverse event reports reveal patterns of complications that warrant further investigation. Even a relatively small number of injuries can trigger significant concern when the affected patient population is highly vulnerable and the potential outcomes include permanent disability.

Blood clot complications can produce a wide range of injuries depending on where the clot forms and where it travels.

Potential consequences may include:

• Reduced blood flow to limbs
• Vascular obstruction
• Tissue death
• Emergency surgical intervention
• Permanent loss of function
• Extended hospitalization
• Additional cardiovascular complications
• Long-term disability

Patients who survive clot-related complications may require ongoing monitoring, additional surgeries, rehabilitation, and future medical care.

Only Six Hospitals Were Reportedly Impacted

Johnson & Johnson MedTech has indicated that the affected products were distributed to six hospitals within the United States.

According to company statements, the impacted hospitals have been contacted and instructed to return the products. The company also stated that credits would be issued for the affected devices.

Although the limited distribution may reduce the total number of potentially affected patients, the seriousness of the reported complications remains significant.

Medical device recalls involving a small number of facilities can still result in substantial litigation when injuries occur. The number of hospitals involved does not determine the severity of patient harm.

Patients who underwent treatment involving an Impella CP with SmartAssist system during the relevant time period may wish to discuss their treatment records with their healthcare providers if concerns arise regarding device usage.

A Growing Number of Safety Concerns Involving the Impella Platform

The latest FDA warning arrives amid a series of recalls and safety communications involving various Impella-related products.

According to publicly reported information, multiple recalls and safety alerts have affected Impella Automated Impella Controllers during 2025. Additional safety concerns reportedly involved purge cassette systems and certain Impella CP with SmartAssist devices.

Repeated recalls do not automatically establish liability in any individual case. However, recurring safety actions involving a product line often attract increased attention from regulators, healthcare providers, patients, and attorneys investigating potential injuries.

When evaluating medical device injury claims, investigators frequently review:

• Prior recalls
• FDA safety communications
• Adverse event reports
• Internal testing records
• Product design history
• Corrective actions taken by manufacturers
• Complaint investigations

A history of repeated safety actions may become relevant when examining whether manufacturers identified risks promptly and implemented appropriate corrective measures.

Product Liability Claims Involving Medical Devices

Medical device manufacturers have a responsibility to design, manufacture, test, and monitor products that can be used safely when physicians follow approved instructions.

When device defects allegedly contribute to patient injuries, affected individuals may pursue legal claims under product liability laws.

Potential allegations may include:

Design Defects

A design defect claim may assert that a medical device contains an inherently unsafe design that creates unreasonable risks during intended use.

Manufacturing Defects

Manufacturing defect claims focus on errors occurring during production that render devices unsafe despite an otherwise acceptable design.

Failure to Warn

Manufacturers may have obligations to provide adequate warnings regarding known or foreseeable risks associated with device usage.

Negligence

Negligence claims may involve allegations that reasonable care was not exercised during product development, testing, monitoring, or post-market safety surveillance.

Each claim requires a detailed review of medical records, regulatory documents, device information, and expert medical analysis.

What Patients and Families Should Know

Patients who underwent treatment involving recalled medical devices may not immediately know whether complications were connected to the product involved.

Potential warning signs following vascular complications can include:

• • Leg pain
  • Numbness
  • Cold extremities
  • Reduced circulation

• Changes in skin color
• Swelling
• Persistent vascular symptoms

Individuals experiencing ongoing medical problems following Impella-related treatment should discuss those concerns with qualified healthcare providers.

Medical records may help determine whether an affected device was used and whether any complications occurred during treatment or recovery.

Contact Parker Waichman LLP For A Free Case Review

Medical devices are often used when patients are facing life-threatening health conditions and have little ability to evaluate the risks for themselves. When a device allegedly contributes to serious complications, patients and families deserve answers.

Parker Waichman LLP is investigating potential claims involving recalled Impella introducer kits and related cardiovascular devices. If you or a loved one suffered vascular complications, blood clot injuries, ischemia, additional surgeries, permanent impairment, or other serious medical problems after treatment involving an Impella system, you may have legal rights.

Parker Waichman LLP represents injured patients nationwide in medical device litigation and product liability claims.

For a free consultation, call 1-800-YOUR-LAWYER (1-800-968-7529) today.

Regardless of your location or where your injury occurred, our nationwide product injury law firm is ready to assist you.